189 related articles for article (PubMed ID: 37172199)
1. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
Bennett J; Ishikawa C; Agarwal P; Yeung J; Sampson A; Uible E; Vick E; Bolanos LC; Hueneman K; Wunderlich M; Kolt A; Choi K; Volk A; Greis KD; Rosenbaum J; Hoyt SB; Thomas CJ; Starczynowski DT
Blood; 2023 Sep; 142(11):989-1007. PubMed ID: 37172199
[TBL] [Abstract][Full Text] [Related]
2. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
Elife; 2022 Aug; 11():. PubMed ID: 36040792
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
Seltzer J; Moorad R; Schifano JM; Landis JT; Dittmer DP
J Virol; 2020 May; 94(10):. PubMed ID: 32161170
[TBL] [Abstract][Full Text] [Related]
4. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.
Smith MA; Choudhary GS; Pellagatti A; Choi K; Bolanos LC; Bhagat TD; Gordon-Mitchell S; Von Ahrens D; Pradhan K; Steeples V; Kim S; Steidl U; Walter M; Fraser IDC; Kulkarni A; Salomonis N; Komurov K; Boultwood J; Verma A; Starczynowski DT
Nat Cell Biol; 2019 May; 21(5):640-650. PubMed ID: 31011167
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling.
De S; Karim F; Kiessu E; Cushing L; Lin LL; Ghandil P; Hoarau C; Casanova JL; Puel A; Rao VR
J Biol Chem; 2018 Sep; 293(39):15208-15220. PubMed ID: 30115681
[TBL] [Abstract][Full Text] [Related]
6. Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases.
Loiarro M; Gallo G; Fantò N; De Santis R; Carminati P; Ruggiero V; Sette C
J Biol Chem; 2009 Oct; 284(41):28093-28103. PubMed ID: 19679662
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists.
Vollmer S; Strickson S; Zhang T; Gray N; Lee KL; Rao VR; Cohen P
Biochem J; 2017 Jun; 474(12):2027-2038. PubMed ID: 28512203
[TBL] [Abstract][Full Text] [Related]
8. IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation of MyD88 adaptor-like (Mal).
Dunne A; Carpenter S; Brikos C; Gray P; Strelow A; Wesche H; Morrice N; O'Neill LA
J Biol Chem; 2010 Jun; 285(24):18276-82. PubMed ID: 20400509
[TBL] [Abstract][Full Text] [Related]
9. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of human IRAK1.
Wang L; Qiao Q; Ferrao R; Shen C; Hatcher JM; Buhrlage SJ; Gray NS; Wu H
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13507-13512. PubMed ID: 29208712
[TBL] [Abstract][Full Text] [Related]
11. Cloning and functional characterization of IRAK1 from rainbow trout (Oncorhynchus mykiss).
Yang YC; Chen SN; Gan Z; Huang L; Nie P
Dev Comp Immunol; 2021 Jan; 114():103780. PubMed ID: 32745481
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
Hosseini MM; Kurtz SE; Abdelhamed S; Mahmood S; Davare MA; Kaempf A; Elferich J; McDermott JE; Liu T; Payne SH; Shinde U; Rodland KD; Mori M; Druker BJ; Singer JW; Agarwal A
Leukemia; 2018 Nov; 32(11):2374-2387. PubMed ID: 29743719
[TBL] [Abstract][Full Text] [Related]
13. A noncanonical IRAK4-IRAK1 pathway counters DNA damage-induced apoptosis independently of TLR/IL-1R signaling.
Li Y; Shah RB; Sarti S; Belcher AL; Lee BJ; Gorbatenko A; Nemati F; Yu H; Stanley Z; Rahman M; Shao Z; Silva JM; Zha S; Sidi S
Sci Signal; 2023 Dec; 16(816):eadh3449. PubMed ID: 38113335
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling.
De Nardo D; Balka KR; Cardona Gloria Y; Rao VR; Latz E; Masters SL
J Biol Chem; 2018 Sep; 293(39):15195-15207. PubMed ID: 30076215
[TBL] [Abstract][Full Text] [Related]
15. Association of Polymorphisms in IRAK1, IRAK4 and MyD88, and Severe Invasive Pneumococcal Disease.
Carrasco-Colom J; Jordan I; Alsina L; Garcia-Garcia JJ; Cambra-Lasaosa FJ; Martín-Mateos MA; Juan M; Muñoz-Almagro C
Pediatr Infect Dis J; 2015 Sep; 34(9):1008-13. PubMed ID: 26075815
[TBL] [Abstract][Full Text] [Related]
16. Two human MYD88 variants, S34Y and R98C, interfere with MyD88-IRAK4-myddosome assembly.
George J; Motshwene PG; Wang H; Kubarenko AV; Rautanen A; Mills TC; Hill AV; Gay NJ; Weber AN
J Biol Chem; 2011 Jan; 286(2):1341-53. PubMed ID: 20966070
[TBL] [Abstract][Full Text] [Related]
17. IRAK1: oncotarget in MDS and AML.
Beverly LJ; Starczynowski DT
Oncotarget; 2014 Apr; 5(7):1699-700. PubMed ID: 24880611
[No Abstract] [Full Text] [Related]
18. MyD88 oligomer size functions as a physical threshold to trigger IL1R Myddosome signaling.
Deliz-Aguirre R; Cao F; Gerpott FHU; Auevechanichkul N; Chupanova M; Mun Y; Ziska E; Taylor MJ
J Cell Biol; 2021 Jul; 220(7):. PubMed ID: 33956941
[TBL] [Abstract][Full Text] [Related]
19. Endotoxin tolerance impairs IL-1 receptor-associated kinase (IRAK) 4 and TGF-beta-activated kinase 1 activation, K63-linked polyubiquitination and assembly of IRAK1, TNF receptor-associated factor 6, and IkappaB kinase gamma and increases A20 expression.
Xiong Y; Qiu F; Piao W; Song C; Wahl LM; Medvedev AE
J Biol Chem; 2011 Mar; 286(10):7905-7916. PubMed ID: 21220427
[TBL] [Abstract][Full Text] [Related]
20. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
Rhyasen GW; Bolanos L; Fang J; Jerez A; Wunderlich M; Rigolino C; Mathews L; Ferrer M; Southall N; Guha R; Keller J; Thomas C; Beverly LJ; Cortelezzi A; Oliva EN; Cuzzola M; Maciejewski JP; Mulloy JC; Starczynowski DT
Cancer Cell; 2013 Jul; 24(1):90-104. PubMed ID: 23845443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
